Business Analytics: Insights from the Life Sciences Sector
In an environment marked by extreme uncertainty, one thing is certain for life sciences companies: they need to be smarter than ever. With profit margins under pressure and reform on the rise, each decision takes on greater importance – especially considered against the backdrop of issues such as healthcare reform and the steady rise of generic drugs in the pharmaceutical marketplace.
How can you fine tune promotional spending to lift overall performance? Which portfolio shifts make sense for which regions? Where are you leaving money on the table with sub-optimal pricing? Companies that build the capabilities to ask these crunchy questions – and answer them with confidence – are the ones who’ll stay ahead. Imagine knowing in advance that your current level of investment in direct selling was going to decline in return, for example. Or having the right insights to drive promotional investments at the local level rather than at the national level. Resource allocation and decision-making in areas such as these can be dramatically improved with business analytics.
Deloitte can help. We know life sciences, and we know where business analytics can deliver the most value. From data management to business intelligence to performance measurement to predictive modeling, we can help you in your efforts to get to the right answers faster.
|When a powerhouse pharmaceutical made a major acquisition
A custom accounting tool facilitates the accounting of adjustments during an acquisition and results in the efficient and effective control of the purchase
|Creating a new formula for drug safety and compliance
Blending the synergies of its leading life sciences R&D practice with a drug safety consulting market leader, Deloitte has acquired Intrasphere, a global drug safety and regulatory consulting business.
|Closing the loop in life sciences analytics
From data management to business intelligence to performance measurement to predictive modeling, we can help you in your efforts to get to the right answers faster.
|New commercial model: Science or swag?
Should you blow up your sales force or stick with the status quo?
|Lead or follow - Should life sciences companies invest in electronic health records or wait?
Should life sciences companies start investing in electronic health records, or wait for things to shake out?